Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Trial of Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia (AML)

NCT03836209 is registered in ClinicalTrials.gov with PrECOG, LLC. as lead sponsor.

NCT NCT03836209
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03836209 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Trial of Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia (AML)
Lead sponsor
PrECOG, LLC.
Phase
Phase 2
Overall status
Completed
Start date
December 6, 2019
Completion date
June 30, 2026
Enrollment
181 (actual)
Sites
44

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia